title: Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix.
abstract: OBJECTIVE
  The prognostic significance of the expression of estrogen receptors (ER) and progesterone receptors (PgR) in adenocarcinoma of the uterine cervix has been controversial. Hence, the relationship between the expression of the hormone receptors and clinical outcome was evaluated for patients with adenocarcinoma treated with radiation therapy alone.
  
  
  METHODS
  This study involved 66 patients with cervical adenocarcinoma consisting of 44 adenocarcinomas and 22 adeno-squamous cell carcinomas. They received radiation therapy at the National Institute of Radiological Sciences Hospital between 1962 and 1993. The mean age of the patients was 62. 0 +/- 12.0 years (range, 36-82 years). The numbers of patients with Stage I, II, III, and IV diseases were 7, 17, 27, and 15, respectively. Their ER and PgR statuses were investigated immunohistochemically using biopsy specimens excised from the cervical tumors before radiation therapy.
  
  
  RESULTS
  ER staining was positive in 12 patients (19%). ER status did not correlate with the 5-year cause-specific, local-control, and disease-free survivals. PgR staining was positive in 12 patients (19%). The disease-free survival rate of PgR-positive patients was significantly higher than that of PgR-negative patients (p = 0.044). Although PgR status did not reach statistical significance in relation to the 5-year cause-specific survival and local-control survival, the better survival was due to less local recurrence rather than to less distant metastasis.
  
  
  CONCLUSIONS
  The present study suggested that PgR status was associated with prognosis after radiation therapy for adenocarcinoma of the uterine cervix.
authors.affiliation: Division of Radiation Medicine, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: T
authors.initials: T
authors.lastname: Arai
authors.forename: S
authors.initials: S
authors.lastname: Morita
authors.forename: H
authors.initials: H
authors.lastname: Tsujii
authors.forename: K
authors.initials: K
authors.lastname: Oka
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018196:Carcinoma, Adenosquamous / Q000737:chemistry* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone